{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Small+Cell+Carcinoma&page=21",
    "query": {
      "condition": "Cervical Small Cell Carcinoma",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 560,
    "total_pages": 56,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Small+Cell+Carcinoma&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Small+Cell+Carcinoma&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T23:06:23.981Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03485209",
      "title": "Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Exocrine Pancreatic Cancer",
        "Carcinoma, Squamous Cell of Head and Neck"
      ],
      "interventions": [
        {
          "name": "tisotumab vedotin",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 350,
      "start_date": "2018-06-25",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-15T23:06:23.981Z",
      "location_count": 124,
      "location_summary": "Encinitas, California • La Jolla, California • Sacramento, California + 57 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03485209"
    },
    {
      "nct_id": "NCT03652077",
      "title": "A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cervical Cancer",
        "Gastric Cancer",
        "Stomach Cancer",
        "Gastroesophageal Junction Cancer",
        "Esophageal Cancer",
        "Hepatocellular Carcinoma",
        "Melanoma",
        "Uveal Melanoma",
        "Merkel Cell Carcinoma",
        "Mesothelioma",
        "MSI",
        "Non-small Cell Lung Cancer",
        "NSCLC",
        "Ovarian Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "RCC",
        "Triple-negative Breast Cancer",
        "Urothelial Carcinoma",
        "Mismatch Repair Deficiency"
      ],
      "interventions": [
        {
          "name": "INCAGN02390",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-09-24",
      "completion_date": "2021-08-18",
      "has_results": false,
      "last_update_posted_date": "2021-11-15",
      "last_synced_at": "2026-10-15T23:06:23.981Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Jackson, Mississippi • Hackensack, New Jersey + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Huntsville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03652077"
    },
    {
      "nct_id": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Urothelial Carcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Merkel Cell Carcinoma",
        "Melanoma",
        "Renal Cell Carcinoma",
        "Gastric Cancer",
        "Cervical Cancer",
        "Hepatocellular Carcinoma",
        "Microsatellite Instability",
        "Mismatch Repair Deficiency",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "N-803 + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Avelumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Pembrolizumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Nivolumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Atezolizumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Avelumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Durvalumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Docetaxel + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Docetaxel + Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-12-11",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-10-15T23:06:23.981Z",
      "location_count": 35,
      "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03228667"
    },
    {
      "nct_id": "NCT05283330",
      "title": "Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cervical Cancer",
        "Breast Cancer",
        "Colon Cancer",
        "NSCLC",
        "mCRPC (Metastatic Castration-resistant Prostate Cancer)",
        "Glioblastoma",
        "Nonsmall Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "²¹²Pb-DOTAM-GRPR1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orano Med Theranostics, SAS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2022-12-22",
      "completion_date": "2032-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-10-15T23:06:23.981Z",
      "location_count": 8,
      "location_summary": "Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Glen Burnie",
          "state": "Maryland"
        },
        {
          "city": "Glen Burnie",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05283330"
    },
    {
      "nct_id": "NCT02543645",
      "title": "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Renal Cell",
        "Kidney Diseases",
        "Kidney Neoplasms",
        "Urogenital Neoplasms",
        "Urologic Diseases",
        "Urologic Neoplasms",
        "Neoplasms by Histologic Type",
        "Neoplasms",
        "Clear-cell Metastatic Renal Cell Carcinoma",
        "Melanoma",
        "Triple Negative Breast Cancer",
        "Bladder Cancer",
        "Head and Neck Cancer",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Combination of Varlilumab and Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2015-10",
      "completion_date": "2017-05-22",
      "has_results": false,
      "last_update_posted_date": "2018-04-30",
      "last_synced_at": "2026-10-15T23:06:23.981Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02543645"
    },
    {
      "nct_id": "NCT00413075",
      "title": "Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "oral belinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Valerio Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2006-06",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2015-07-08",
      "last_synced_at": "2026-10-15T23:06:23.981Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00413075"
    },
    {
      "nct_id": "NCT04458259",
      "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "PF-07265807",
          "type": "DRUG"
        },
        {
          "name": "Sasanlimab",
          "type": "DRUG"
        },
        {
          "name": "Axitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2020-09-24",
      "completion_date": "2024-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-10-15T23:06:23.981Z",
      "location_count": 25,
      "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04458259"
    },
    {
      "nct_id": "NCT00738751",
      "title": "Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Panobinostat (LBH589)",
          "type": "DRUG"
        },
        {
          "name": "erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2008-11",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2015-02-04",
      "last_synced_at": "2026-10-15T23:06:23.981Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00738751"
    },
    {
      "nct_id": "NCT04491942",
      "title": "Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Bile Duct Carcinoma",
        "Advanced Breast Carcinoma",
        "Advanced Cervical Carcinoma",
        "Advanced Endometrial Carcinoma",
        "Advanced Esophageal Carcinoma",
        "Advanced Gastric Carcinoma",
        "Advanced Head and Neck Carcinoma",
        "Advanced Lung Non-Small Cell Carcinoma",
        "Advanced Lung Small Cell Carcinoma",
        "Advanced Malignant Solid Neoplasm",
        "Advanced Ovarian Carcinoma",
        "Advanced Penile Carcinoma",
        "Advanced Pleural Malignant Mesothelioma",
        "Advanced Urothelial Carcinoma",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Stage III Cervical Cancer AJCC v8",
        "Stage III Distal Bile Duct Cancer AJCC v8",
        "Stage III Intrahepatic Bile Duct Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Penile Cancer AJCC v8",
        "Stage III Pleural Diffuse Malignant Mesothelioma AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Distal Bile Duct Cancer AJCC v8",
        "Stage IV Intrahepatic Bile Duct Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Penile Cancer AJCC v8",
        "Stage IV Pleural Diffuse Malignant Mesothelioma AJCC v8",
        "Triple-Negative Breast Carcinoma",
        "Unresectable Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Elimusertib",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2021-08-25",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-15T23:06:23.981Z",
      "location_count": 7,
      "location_summary": "Sacramento, California • Bethesda, Maryland • New York, New York + 3 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04491942"
    },
    {
      "nct_id": "NCT04695847",
      "title": "M1231 in Participants With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumors",
        "Esophageal Cancer",
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "M1231",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2021-01-13",
      "completion_date": "2023-06-23",
      "has_results": false,
      "last_update_posted_date": "2023-07-07",
      "last_synced_at": "2026-10-15T23:06:23.981Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04695847"
    }
  ]
}